Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘IDO Inhibitors’

National Harbor, MD – Day 2 of #SITC17 brought some interesting highlights on a number of fronts, not all of which may be apparent at present, but there are a few readouts that will have a broader impact going forward.

SITC 2017 Stars?

As we move into an era where we see more combinations evolve in immuno-onology, things are likely to get more confusing rather than less so and it could well be another 3-5 years before things truly settle down and more concrete trends emerge.

Here, we reviewed 10 different areas of interest with a strong clinical relevance and explored the topics further.

Please note that some of these will also have follow-on posts with thought leader interviews and related poster reviews.

To learn more insights on the latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.

IDO/TDO inhibition is a topic we’ve been following the progress on for several years now with various updates along the way. It’s also one of our most requested Previews for this year’s ASCO meeting taking place next month.

The Bean, Chicago

In Chicago next month, initial data from several trials is due to be presented.

  • What can we expect?
  • How are the main players in this landscape doing?
  • Will this combination be the next big thing in the oncology IO space?

In our latest #ASCO17 Preview, we take a hard look at IDO/TDO inhibitors.

Subscribers can login to read our latest expert interview

It’s a funny old world sometimes… I was planning to post a mini series on immuno-oncology presentations from ESMO this week and review what we had learned from the new data, good and not so good. This morning’s sudden announcement from Genentech regarding their latest collaboration is therefore rather timely:

“An exclusive worldwide licensing agreement and research collaboration with NewLink Genetics for the discovery and development of IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitors for the potential treatment of cancer.”

There are a number of reasons why they might do this that make a lot of solid scientific sense.

To learn more about our insights, subscribers can log-in.

error: Content is protected !!